PMID- 12210436
OWN - NLM
STAT- MEDLINE
DCOM- 20021203
LR  - 20191210
IS  - 0146-6615 (Print)
IS  - 0146-6615 (Linking)
VI  - 68
IP  - 1
DP  - 2002 Sep
TI  - Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently 
      infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence 
      of foscarnet-resistant virus originating from the ACV(r) virus.
PG  - 99-104
AB  - A human leukocyte antigen (HLA)-matched unrelated bone marrow transplantation 
      (BMT) was performed in a 13-year-old patient with the congenital immunodeficiency 
      syndrome, Wiskott-Aldrich syndrome. The patient had a history of acyclovir 
      (ACV)-resistant (ACV(r)) herpes simplex virus type 1 (HSV-1) infections prior to 
      BMT. After BMT, the skin lesions caused by HSV-1 relapsed on the face and 
      genito-anal areas. Ganciclovir (GCV) therapy was initiated, but the mucocutaneous 
      lesions worsened. An HSV-1 isolate recovered from the lesions during this episode 
      was resistant to both ACV and GCV. The ACV(r) isolate was confirmed to have the 
      same mutation in the viral thymidine kinase (TK) gene as that of the previously 
      isolated ACV(r) isolates from the patient. After treatment switch to foscarnet 
      (PFA), there was a satisfactory remission but not a complete recovery. Although 
      the mucocutaneous lesions improved, a PFA-resistant (PFA(r)) HSV-1 was isolated 1 
      month after the start of PFA therapy. The PFA(r) HSV-1 isolate coded for the same 
      mutation in the viral TK gene as the ACV(r) HSV-1 isolates. Furthermore, the 
      PFA(r) isolate also expressed a mutated viral DNA polymerase (DNA pol) with an 
      amino acid (Gly) substitution for Val at position 715. This is the first report 
      on the clinical course of a BMT-associated ACV(r) HSV-1 infection that 
      subsequently developed resistance to foscarnet as well.
CI  - Copyright 2002 Wiley-Liss, Inc.
FAU - Saijo, Masayuki
AU  - Saijo M
AD  - Special Pathogens Laboratory, Department of Virology 1, National Institute of 
      Infectious Diseases, Tokyo, Japan. msaijo@nih.go.jp
FAU - Yasuda, Yukiharu
AU  - Yasuda Y
FAU - Yabe, Hiromasa
AU  - Yabe H
FAU - Kato, Shunichi
AU  - Kato S
FAU - Suzutani, Tatsuo
AU  - Suzutani T
FAU - De Clercq, Erik
AU  - De Clercq E
FAU - Niikura, Masahiro
AU  - Niikura M
FAU - Maeda, Akihiko
AU  - Maeda A
FAU - Kurane, Ichiro
AU  - Kurane I
FAU - Morikawa, Shigeru
AU  - Morikawa S
LA  - eng
SI  - GENBANK/AB047358
SI  - GENBANK/AB047365
SI  - GENBANK/AB070847
SI  - GENBANK/AB070848
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 364P9RVW4X (Foscarnet)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.7.7 (DNA-Directed DNA Polymerase)
RN  - X4HES1O11F (Acyclovir)
SB  - IM
MH  - Acyclovir/*pharmacology
MH  - Adolescent
MH  - Animals
MH  - Antiviral Agents/*pharmacology
MH  - Base Sequence
MH  - *Bone Marrow Transplantation
MH  - Cell Line
MH  - Chlorocebus aethiops
MH  - DNA, Viral
MH  - DNA-Directed DNA Polymerase/genetics
MH  - Drug Resistance, Viral
MH  - Foscarnet/*pharmacology
MH  - Herpes Simplex/complications/physiopathology/*virology
MH  - Herpesvirus 1, Human/*drug effects/genetics
MH  - Humans
MH  - Male
MH  - Molecular Sequence Data
MH  - Reverse Transcriptase Inhibitors/*pharmacology
MH  - Thymidine Kinase/genetics
MH  - Vero Cells
MH  - *Virus Latency
MH  - Wiskott-Aldrich Syndrome/complications/*virology
EDAT- 2002/09/05 10:00
MHDA- 2002/12/04 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2002/12/04 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 10.1002/jmv.10175 [doi]
PST - ppublish
SO  - J Med Virol. 2002 Sep;68(1):99-104. doi: 10.1002/jmv.10175.